Lung EpiCheck Biomarkers Development Study
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Checked against the public recordLast updated Feb 12, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Nucleix Ltd.
- Interventions being studied
- Other: Blood collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria - Cases: * Age 50-80 years * Subjects who are currently smoking or former smokers, with at least 20 pack-years * Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology. Exclusion Criteria - Cases * Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer Inclusion Criteria - USPSTF risk * Age 50-80 years * Subjects who are currently smoking or former smokers, with at least 20 pack-years Exclusion Criteria - USPSTF risk \- Known diagnosis or treatment of cancer of any kind in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix Inclusion Criteria - Healthy controls * Age 20-80 years * Never smoker or current / previous smoker \< 20 pack year history Exclusion Criteria - Healthy Controls * Known diagnosis or treatment of cancer of any kind in the past (lifetime), except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix. * Not previously diagnosed with a lung lesion highly suspicious for cancer * Under follow up or work up for any lesion suspicious for any type of cancer * Presenting with fever with body temperature 100.4°F (38°C) or higher * Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw * Pregnancy * Any history of blood product transfusion within 30 days prior to blood draw
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Life Spring Clinical ResearchMiami, Florida
- Emerald Coast OBGYNPanama City, Florida
- Ochsner LSU Health Shreveport - Regional UrologyShreveport, Louisiana
- Comprehensive UrologySouthfield, Michigan
- Michigan Institute of Urology, P.C.Troy, Michigan
- Urology San AntonioSan Antonio, Texas
- National Koranyi Institute for PulmonologyBudapest
- Carmel Medical CenterHaifa
- Sourasky Medical CenterTel Aviv
- ZGT Medical CenterHengelo
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 12, 2024. Always confirm current availability with the study team.